ClinicalTrials.gg
CompletedNCT04161482Updated Jul 10, 2020

An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

A Phase 1 interventional study of Furosemide 80 mg (8 mg/mL) in Healthy, sponsored by scPharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 45 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by scPharmaceuticals, Inc. (part of Mannkind Corporation) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
45 Years to 80 Years
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.

Read the detailed description

Furoscix 80 mg will be administered as a subcutaneous infusion following a step-wise decrease in infusion times starting with a 5 hour infusion time. Subsequent cohorts will enroll following a safety assessment of the prior cohort. While maintaining the 80 mg dose, infusion time will ultimately be reduced to 30 minutes.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

scPharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible for inclusion only if all of the following criteria are met:

  1. An Institutional Review Board (IRB) approved is signed and dated prior to any study-related activities.
  2. Male and female Subjects 45-80 years of age.
  3. Have the ability to understand the requirements of the study and is willing to comply with all study procedures.
  4. In the opinion of the investigator, able to participate in the study.

Exclusion criteria

Exclusion Criteria:

A Subject is not eligible for inclusion if any of the following criteria apply:

  1. Receipt of loop diuretics (furosemide, bumetanide or torsemide) or thiazide diuretics (hydrochlorothiazide or metolazone) within 24 hours of study drug.
  2. Receipt of potassium-sparing diuretics (spironolactone, amiloride) or oral calcium, potassium or magnesium supplements (including multi-vitamins) within 24 hours of study drug.
  3. History of allergy to furosemide, sulfonamides or other loop diuretics.
  4. Any skin conditions currently requiring medical therapy.
  5. History of diabetes.
  6. Presence or need for urinary catheterization, urinary tract abnormality or disorder interfering with urination.
  7. Serum sodium \<130 mEq/L at screening.
  8. Serum potassium \< 3.5 or > 5.5 mEq/L at screening.
  9. Serum magnesium \< 1.5 or > 2.5 mEq/L at screening.
  10. Serum chloride \< 96 or > 106 mEq/L at screening.
  11. Serum calcium \< 8.5 or > 10.5 mg/dL at screening.
  12. Estimated (GFR) \< 30 mL/min/1.73 m2 by simplified Modification of Diet in Renal Disease (sMDRD) equation at screening.
  13. Systolic BP (SBP) \< 90 mm Hg at screening or baseline.
  14. Heart rate > 110 beats per minute (BPM) at screening or baseline.
  15. History of tinnitus or hearing impairment, including deafness.
  16. Temperature > 38°C (oral or equivalent) at screening or baseline.
  17. Blood alcohol concentration > 2 mg/dL (0.02%) at screening or baseline.
  18. Female Subject who is pregnant or lactating.
  19. History of major abdominal surgery affecting the needle placement site.
  20. History of benign prostatic hyperplasia (BPH), prostatitis or prostate cancer.
  21. Urinary retention due to bladder emptying disorders and/or urethral narrowing.
  22. History of liver disease, cirrhosis, or ascites.
  23. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
  24. Allergies and/or sensitivities to adhesive bandages or medical tape.
  25. Any surgical or medical condition which in the opinion of the Investigator may interfere with participation in the study or which may affect the outcome of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Cohort One

    A bi-phasic delivery over 5 hours

    Drug: Furosemide 80 mg (8 mg/mL)

  • Experimental
    Cohort 2a

    Continuous infusion over 2 hours

    Drug: Furosemide 80 mg (8 mg/mL)

  • Experimental
    Cohort 2b

    Bi-phasic delivery over 2 hours

    Drug: Furosemide 80 mg (8 mg/mL)

  • Experimental
    Cohort 3

    Continuous infusion over 1 hour.

    Drug: Furosemide 80 mg (8 mg/mL)

  • Experimental
    Cohort 4

    Continuous infusion over 30 minutes.

    Drug: Furosemide 80 mg (8 mg/mL)

Interventions

  • DrugFurosemide 80 mg (8 mg/mL)

    Drug page: Furosemide

    Furoscix will be administered as a subcutaneous infusion.

06

What researchers measure

Primary outcomes

  1. Infusion Site Pain (11 Point Pain Scale)

    Assessment of pain will be conducted upon placement of the subcutaneous (SC) needle, upon activation of SC infusion and periodically during the infusion and post-infusion completion for up to 8 hours after the start of the infusion using a standardized 11 point pain scale. Score will range from 0 to 10, where zero is equivalent to no pain and 10 is equivalent to the worst possible pain.

    Time frame: 8 hours

Secondary outcomes

  1. Safety (Adverse Events)

    Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) will be assessed from the start of study drug administration through 24-48 hours after the start of the infusion.

    Time frame: Hours 1-8 and at the 24-48 hour follow up visit.

07

Study locations

1 site
  • Aventiv Clinical Research
    Columbus, Ohio 42313, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jun 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2019
First posted
Nov 13, 2019
StartActual
Dec 2, 2019
Primary completionActual
Jun 24, 2020
CompletionActual
Jun 26, 2020
Last update
Jul 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04161482
Collaborators
Clinical Trial Data Services, Inc., CSSi Life Sciences
Responsible party
Sponsor
First posted
Nov 13, 2019
Start date
Dec 2, 2019
Primary completion
Jun 24, 2020
Completion
Jun 26, 2020
Last update
Jul 10, 2020

Study contacts

Samir Arora, MD
principal investigator · Aventiv Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion